US · Healthcare

Akari Therapeutics PLC (AKTX)

Biotechnology

Akari Therapeutics PLC (AKTX) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-05-23, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for AKTX

P/E ratio

25.00

Akari Therapeutics PLC (AKTX) — FAQ

What is AKTX's P/E ratio?

The price-to-earnings (P/E) ratio for Akari Therapeutics PLC (AKTX) is 25.00 (data as of 2026-05-23).

Does Akari Therapeutics PLC pay a dividend?

Dividend yield is not available in the current snapshot for Akari Therapeutics PLC (AKTX). Check the MyAverix Finance app for the latest dividend data.

What sector is Akari Therapeutics PLC in?

Akari Therapeutics PLC (AKTX) is classified in the Healthcare sector (Biotechnology industry).

What exchange is AKTX listed on?

AKTX is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)